GlassScriptPhysician profile
Javier Emilio Marinez
NPI 1679696983
$6,974.90
in general payments reported to CMS, 2019-2025
23 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $371 · 2021: $1,434 · 2022: $2,505 · 2023: $536 · 2024: $742 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546 · Education: $92.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.20 |
| Education | $92.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $2,551.93 | 2021-2022 | |
| Melinta Therapeutics, LLC | $929.46 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Insmed, INC. | $924.40 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $447.95 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Paratek Pharmaceuticals, INC. | $294.54 | 2021-2025 | Nuzyra |
| Astellas Pharma US INC | $234.93 | 2019-2024 | Cresemba |
| La Jolla Pharmaceutical Company | $187.75 | 2022-2024 | Xerava |
| Gilead Sciences, INC. | $180.05 | 2019-2023 | |
| Smith+Nephew, INC. | $170.88 | 2024-2025 | Grafix Pl, Renasys Touch |
| Takeda Pharmaceuticals U.S.A., INC. | $150.71 | 2021-2024 | Livtencity |
| Janssen Biotech, INC. | $150.47 | 2019 | |
| Mimedx Group, INC. | $139.70 | 2024 | |
| Shionogi INC | $122.75 | 2020-2024 | Fetroja |
| Tetraphase Pharmaceuticals, INC. | $93.72 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $75.53 | 2019-2025 | Vibativ |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $72.81 | 2023-2025 | Vowst |
| Abbvie INC. | $70.75 | 2023-2025 | |
| Allergan, INC. | $68.88 | 2019-2020 | |
| Urgo Medical North America, LLC | $36.68 | 2024-2025 | Urgoclean Ag, Urgok2 |
| Ferring Pharmaceuticals INC. | $19.81 | 2023 | Rebyota |
| Reprise Biomedical, INC. | $19.11 | 2025 | Miro3d |
| Shire North American Group INC | $16.11 | 2019 | |
| Nabriva Therapeutics, Plc | $15.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Marinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.